Revvity 2025 Q2 Earnings Sustained Profitability Amid Slight Earnings Decline

Revvity reported its fiscal 2025 Q2 earnings on Aug 05, 2025, delivering a mixed set of results. The company met or exceeded key revenue expectations and raised full-year guidance, though net income declined slightly. This outcome reflects continued resilience in the business despite ongoing macroeconomic headwinds.

Revenue
Revvity reported total revenue of $720.28 million for the second quarter of 2025, a 4.1% increase from $691.68 million in the same period a year prior. The Life Sciences segment contributed $365.90 million in revenue, reflecting steady demand for instruments, reagents, and imaging technologies, while the Diagnostics segment added $354.39 million, driven by early detection platforms and infectious disease testing solutions.

Earnings/Net Income
The company’s earnings per share (EPS) rose 2.2% to $0.46 in Q2 2025, up from $0.45 in Q2 2024. However, net income slightly declined to $53.95 million in the most recent quarter, down from $55.36 million a year ago. Despite this minor contraction, Revvity has maintained profitability for over 20 consecutive years in this reporting period, underscoring its strong operational discipline.

Price Action
Revvity’s stock edged up 0.43% in the latest trading day but faced downward pressure in the broader timeframe, with a 6.13% drop over the past week and a 12.47% decline month-to-date.

Post-Earnings Price Action Review
A strategy of buying RVTY after an earnings beat and selling after 30 days underperformed significantly, resulting in a -23.78% return versus a benchmark gain of 86.40%. The approach also exhibited a maximum drawdown of 0.00%, a Sharpe ratio of -0.16, and a volatility of 33.52%, indicating suboptimal risk-adjusted returns post-earnings.

CEO Commentary
John R. Coggs, President and CEO, attributed the company’s strong Q2 performance to robust demand across core markets and favorable pricing execution. While supply chain challenges and inflationary pressures remain, Coggs emphasized ongoing investments in R&D and digital transformation to strengthen the company’s market position, particularly in life sciences and diagnostics. He expressed confidence in the business’s ability to sustain long-term growth, citing a strong product pipeline and customer relationships, as well as a continued focus on operational efficiency.

Guidance
Revvity raised its full-year 2025 revenue guidance to a range of $2.84–$2.88 billion, factoring in foreign currency exchange rate changes and anticipating 2–4% organic growth. The company also adjusted its adjusted EPS guidance to $4.85–$4.95. These updates reflect continued momentum in key segments and a stable pricing and cost management environment.

Additional News
Blueshift Asset Management LLC recently acquired 3,529 shares of Revvity, valued at approximately $373,000, marking a new position in the company’s stock. Meanwhile, several major institutional investors, including T. Rowe Price Investment Management Inc. and EdgePoint Investment Group Inc., increased their holdings in RVTY in Q4 2024, with ownership percentages rising significantly. Institutional investors and hedge funds collectively own 86.65% of the company’s shares. On the analyst front, UBS Group upgraded its rating to “buy” and lowered its price target to $115.00, while Raymond James Financial and Evercore ISI also adjusted their price objectives downward but maintained positive ratings. MarketBeat.com reports a consensus rating of “Moderate Buy” with an average price target of $120.07. Additionally, Revvity announced a quarterly dividend of $0.07 per share, payable on November 7, 2025, with a dividend payout ratio of 11.86%.